The Nanocarrier Landscape─Evaluating Key Drug Delivery Vehicles and Their Capabilities: A Translational Perspective
Source abstract
Abstract
The field of nanomedicine is currently in a revolutionary phase, propelled by the significant potential of nanoparticles, which offer several advantages over traditional drug delivery systems. The purpose of this paper is to aggregate contemporary knowledge of nanoparticles developed and applied in drug delivery across major disease classes. Accordingly, we offer, through a thorough search of the literature, a comprehensive overview of the prevalent nanoparticles used in drug delivery systems, covering polymeric, lipid-based, inorganic, and carbon-based nanoparticles, and discuss their advantages and limitations. This work primarily focuses on studies published in the last 5 years, aiming to provide an up-to-date assessment of the critical nanoparticles in drug delivery. Narratively, we synthesize a comprehensive overview of the state-of-the-art in nanocarrier technology, providing in-depth insights into the key nanoparticle types presented in the contemporary literature, their fundamental benefits, potential clinical applications, and limitations impeding their development and adoption. We note that there are gaps and opportunities for concerted efforts focused on developing biocompatible and biodegradable nanoparticles, establishing scalable and cost-effective manufacturing processes, and addressing regulatory challenges associated with nanoparticle-based drug delivery systems. These challenges persist despite the immense translational success of nanoparticle-based drug delivery systems and necessitate continued interdisciplinary research and cross-industry collaboration among scientists, clinicians, and regulatory bodies.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Nanoparticle-Based Drug Delivery · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
SUNUM Nanotechnology Research and Application Centre
Sabanci University
Pharmaceutical Sciences Research Center
Ardabil University of Medical Sciences
Gebze Technical University
Department of Environmental Engineering
Department of Bioengineering, Royal School of Mines
Imperial College London
References (100+)
Show source-provided references
1. 10.3390/MOLECULES2619590510.3390/MOLECULES26195905 ↗
2. 10.1007/s10311-018-00841-110.1007/s10311-018-00841-1 ↗
3. 10.2147/DDDT.S44749610.2147/DDDT.S447496 ↗
4. 10.1038/s41392-023-01642-x10.1038/s41392-023-01642-x ↗
5. 10.1021/acsabm.3c0092410.1021/acsabm.3c00924 ↗
6. 10.1016/j.nano.2019.10213210.1016/j.nano.2019.102132 ↗
7. 10.3390/ijms22211145710.3390/ijms222111457 ↗
8. 10.1016/j.addr.2020.06.00210.1016/j.addr.2020.06.002 ↗
9. 10.1016/j.bbagen.2019.04.01910.1016/j.bbagen.2019.04.019 ↗
10. 10.3390/pharmaceutics1506161010.3390/pharmaceutics15061610 ↗
11. 10.1038/s41598-024-51801-510.1038/s41598-024-51801-5 ↗
12. 10.1021/acsomega.2c0784010.1021/acsomega.2c07840 ↗
13. 10.1038/s41598-023-27729-710.1038/s41598-023-27729-7 ↗
14. 10.1021/acs.chemrestox.3c0017710.1021/acs.chemrestox.3c00177 ↗
15. 10.1016/j.clinthera.2023.08.01710.1016/j.clinthera.2023.08.017 ↗
16. 10.3390/bioengineering704012610.3390/bioengineering7040126 ↗
17. 10.1007/978-3-031-49744-5_510.1007/978-3-031-49744-5_5 ↗
18. 10.1021/acs.molpharmaceut.2c0088210.1021/acs.molpharmaceut.2c00882 ↗
19. 10.1038/s41598-020-75253-910.1038/s41598-020-75253-9 ↗
20. 10.3390/ijms2308415310.3390/ijms23084153 ↗
21. 10.3390/ijms2403275710.3390/ijms24032757 ↗
22. 10.3389/fmolb.2020.0019310.3389/fmolb.2020.00193 ↗
23. 10.2174/187152062066620092411041810.2174/1871520620666200924110418 ↗
24. 10.1186/s12951-023-01826-110.1186/s12951-023-01826-1 ↗
25. 10.3390/cancers1304067010.3390/cancers13040670 ↗
26. 10.1021/acsabm.2c0100010.1021/acsabm.2c01000 ↗
27. 10.1016/j.addr.2023.11482210.1016/j.addr.2023.114822 ↗
28. 10.3390/jnt302000710.3390/jnt3020007 ↗
29. 10.2174/011871520629559824021511291010.2174/0118715206295598240215112910 ↗
30. 10.1021/acs.jpclett.8b0328410.1021/acs.jpclett.8b03284 ↗
31. 10.3389/fbioe.2020.0087910.3389/fbioe.2020.00879 ↗
32. 10.1002/adhm.20180100210.1002/adhm.201801002 ↗
33. 10.1021/acsami.3c1006510.1021/acsami.3c10065 ↗
34. 10.1016/j.nxnano.2024.10012910.1016/j.nxnano.2024.100129 ↗
35. 10.1021/cbe.3c0002310.1021/cbe.3c00023 ↗
36. 10.1021/acsabm.3c0106410.1021/acsabm.3c01064 ↗
37. 10.1016/j.jcis.2022.05.00710.1016/j.jcis.2022.05.007 ↗
38. 10.1038/s43586-022-00104-y10.1038/s43586-022-00104-y ↗
39. 10.1021/acs.chemrev.3c0070510.1021/acs.chemrev.3c00705 ↗
40. 10.1016/j.biomaterials.2020.11992910.1016/j.biomaterials.2020.119929 ↗
41. 10.3390/ijms1906154910.3390/ijms19061549 ↗
42. 10.3390/pharmaceutics1310171610.3390/pharmaceutics13101716 ↗
43. 10.1021/acs.biomac.2c0082310.1021/acs.biomac.2c00823 ↗
44. 10.3389/fbioe.2023.117715110.3389/fbioe.2023.1177151 ↗
45. 10.1201/9781003056003-310.1201/9781003056003-3 ↗
46. 10.3390/pharmaceutics1509223310.3390/pharmaceutics15092233 ↗
47. 10.3390/jfb1001000410.3390/jfb10010004 ↗
48. 10.1002/anbr.20210010910.1002/anbr.202100109 ↗
49. Beola L. · 2018
50. 10.1016/j.jpba.2020.11364210.1016/j.jpba.2020.113642 ↗
51. 10.3390/nano904063810.3390/nano9040638 ↗
52. 10.2217/nnm-2023-035810.2217/nnm-2023-0358 ↗
53. 10.1016/j.ijpharm.2022.12246410.1016/j.ijpharm.2022.122464 ↗
54. 10.1016/j.jddst.2019.02.01710.1016/j.jddst.2019.02.017 ↗
55. 10.1016/j.biopha.2020.11069510.1016/j.biopha.2020.110695 ↗
56. 10.1016/j.jddst.2023.10462310.1016/j.jddst.2023.104623 ↗
57. 10.1021/acsnano.3c0608510.1021/acsnano.3c06085 ↗
58. 10.2174/012211738527551423112706273010.2174/0122117385275514231127062730 ↗
59. 10.1016/j.jddst.2020.10219410.1016/j.jddst.2020.102194 ↗
60. 10.1007/s00508-021-01922-y10.1007/s00508-021-01922-y ↗
61. 10.1021/acs.accounts.1c0054410.1021/acs.accounts.1c00544 ↗
62. 10.1016/j.addr.2020.06.02010.1016/j.addr.2020.06.020 ↗
63. 10.3390/pharmaceutics1507186810.3390/pharmaceutics15071868 ↗
64. 10.2147/IJN.S27909410.2147/IJN.S279094 ↗
65. 10.1016/j.pdpdt.2023.10331210.1016/j.pdpdt.2023.103312 ↗
66. 10.1080/17425247.2022.204702010.1080/17425247.2022.2047020 ↗
67. 10.3390/nano1101003210.3390/nano11010032 ↗
68. 10.1016/j.jddst.2021.10294610.1016/j.jddst.2021.102946 ↗
69. 10.3390/gels902012110.3390/gels9020121 ↗
70. 10.34133/cbsystems.001910.34133/cbsystems.0019 ↗
71. 10.2174/221173851066622060610290610.2174/2211738510666220606102906 ↗
72. 10.1016/j.biopha.2020.11083410.1016/j.biopha.2020.110834 ↗
73. 10.3389/fnano.2021.64456410.3389/fnano.2021.644564 ↗
74. 10.3390/molecules2606158610.3390/molecules26061586 ↗
75. 10.1007/978-981-16-4923-3_610.1007/978-981-16-4923-3_6 ↗
76. 10.3390/ijms22211178310.3390/ijms222111783 ↗
77. 10.1016/j.inoche.2023.11102010.1016/j.inoche.2023.111020 ↗
78. 10.1016/j.drudis.2024.10391510.1016/j.drudis.2024.103915 ↗
79. 10.2174/156802662166621070114412410.2174/1568026621666210701144124 ↗
80. 10.1021/acsnano.0c0879010.1021/acsnano.0c08790 ↗
81. 10.1016/j.jorganchem.2022.12242210.1016/j.jorganchem.2022.122422 ↗
82. 10.1016/j.steroids.2022.10909110.1016/j.steroids.2022.109091 ↗
83. 10.3390/biom1007098010.3390/biom10070980 ↗
84. 10.1515/dmpt-2018-003210.1515/dmpt-2018-0032 ↗
85. 10.3390/nano1321288710.3390/nano13212887 ↗
86. 10.1186/s12951-021-00824-510.1186/s12951-021-00824-5 ↗
87. 10.1016/j.carbpol.2023.12054710.1016/j.carbpol.2023.120547 ↗
88. 10.1016/j.cej.2023.14142610.1016/j.cej.2023.141426 ↗
89. 10.1515/ntrev-2022-054610.1515/ntrev-2022-0546 ↗
90. 10.2174/187152062166621091008421610.2174/1871520621666210910084216 ↗
91. 10.3390/pharmaceutics1503077410.3390/pharmaceutics15030774 ↗
92. 10.1021/acsami.5c0076310.1021/acsami.5c00763 ↗
93. 10.1021/acsami.4c1335810.1021/acsami.4c13358 ↗
94. 10.1016/j.mtchem.2021.10047410.1016/j.mtchem.2021.100474 ↗
95. 10.1021/acsanm.4c0510010.1021/acsanm.4c05100 ↗
96. 10.1021/ACSAMI.4C0253210.1021/ACSAMI.4C02532 ↗
97. 10.1002/slct.20210349510.1002/slct.202103495 ↗
98. 10.1016/j.mtbio.2022.10034910.1016/j.mtbio.2022.100349 ↗
99. 10.1016/j.molliq.2022.11867610.1016/j.molliq.2022.118676 ↗
100. 10.1021/acs.jafc.4c0820210.1021/acs.jafc.4c08202 ↗